Redirecting innate immune signaling

Synedgen's first-in-class therapeutics improve patient outcomes by modulating innate immune signaling to control inflammation and regeneration

First-In-Class Therapies to Protect, Restore, and Repair the Body

Targeted therapies

Scalable GMP production

Excellent safety profiles

Strong IP Position

Protecting the gastrointestinal (GI) tract from cancer therapy

Synedgen’s current lead asset is MIIST305, a clinic-ready, orally delivered, immunomodulatory drug that repairs GI injury regardless of instigating factor. MIIST305 directs innate mucosal responses to restore GI function and reduce unchecked inflammation and damage. MIIST305 has been shown to be effective in response to several animal models of injury to the gut, including chemical-induced models of Crohn’s and colitis, bacterial damage, as well as acute and chronic radiation injury.